Testing Epithelial Permeability in Fetal Tissue-Derived Enteroids
June 16th, 2022
2.3K views
This protocol details the establishment of enteroids, a three-dimensional intestinal model, from fetal intestinal tissue. Immunofluorescent imaging of epithelial biomarkers was used for model characterization. Apical exposure of lipopolysaccharides, a bacterial endotoxin, using microinjection technique induced epithelial permeability in a dose-dependent manner measured by the leakage of fluorescent dextran.
Overview
This protocol outlines the establishment of enteroids from fetal intestinal tissue, providing a three-dimensional model for studying intestinal permeability. The method includes immunofluorescent imaging to characterize the model and assess epithelial permeability in response to lipopolysaccharides.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Gastroenterology
Background
- Enteroids serve as a model for studying gut epithelial function.
- This model mimics the gut luminal environment, allowing for permeability studies.
- Understanding leaky gut disease is crucial for gastrointestinal health.
- The protocol can also be adapted for vascular studies.
Purpose of Study
- To establish a reliable in vitro model of intestinal epithelium.
- To investigate factors influencing epithelial permeability.
- To provide insights into conditions that lead to vascular leakage.
Methods Used
- Preparation of fetal intestinal tissue and enteroid culture.
- Immunofluorescence staining for epithelial biomarkers.
- Microinjection of Dextran-FITC to assess permeability.
- Measurement of Dextran concentration to evaluate permeability changes.
Main Results
- Characterization of enteroids confirmed their epithelial origin.
- Microinjection successfully induced permeability changes.
- LPS exposure increased permeability in a dose-dependent manner.
- EGTA was used as a positive control for permeability assessment.
Conclusions
- The enteroid model is effective for studying intestinal permeability.
- This protocol can aid in understanding leaky gut mechanisms.
- Future applications may extend to vascular permeability studies.
Frequently Asked Questions
What are enteroids?
Enteroids are three-dimensional intestinal models derived from fetal intestinal tissue, used to study gut epithelial function.
How is permeability measured in this study?
Permeability is assessed by microinjecting Dextran-FITC and measuring its concentration in the media.
What is the significance of using LPS in this protocol?
LPS is used to induce epithelial permeability changes, allowing for the study of gut barrier function.
Can this protocol be adapted for other systems?
Yes, it can be applied to endothelial or vascular systems to study vascular leakage.
What precautions should be taken during the procedure?
Care should be taken to maintain the shape of enteroids and avoid losing them during staining and mounting.
Executive Industry Relevance
Human fetal tissue-derived enteroids provide a physiologically relevant in vitro system for interrogating epithelial barrier function and permeability mechanisms in preterm intestinal injury. This model enables quantitative assessment of tight junction integrity and response to pathogenic stimuli, supporting predictive confidence in early-stage target validation and mechanistic de-risking. The approach addresses a critical gap where direct human studies are not feasible, informing risk-adjusted portfolio decisions in gastrointestinal and neonatal research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic interrogation of epithelial barrier disruption by quantifying permeability changes in response to defined stimuli.
- Supports functional validation of tight junction protein targets implicated in leaky gut and mucosal injury.
- Facilitates biological de-risking by modeling disease-relevant epithelial responses to bacterial endotoxins.
- Provides a platform for hypothesis-driven evaluation of candidate modulators of barrier integrity.
Screening & Assay Development
- Establishes a reproducible, three-dimensional enteroid system for standardized permeability assays.
- Delivers quantitative, scalable readouts via dextran leakage measurements for compound screening.
- Enables assay standardization and cross-study comparability through immunofluorescent characterization of tight junctions.
- Prepares validated biological systems for downstream screening of permeability modulators.
Translational & Preclinical Research
- Aligns with disease-relevant mechanisms by modeling preterm intestinal injury and dysbiosis-driven barrier dysfunction.
- Supports translational continuity by enabling cytokine profiling and RNA sequencing from the same enteroid samples.
- Informs preclinical risk assessment by quantifying dose-dependent effects of pathogenic exposures.
- Provides predictive de-risking for therapeutic strategies targeting epithelial integrity.
Pipeline & Workflow Integration
This enteroid-based permeability assay integrates into the discovery-to-preclinical continuum, bridging early mechanistic studies with translational biomarker development in gastrointestinal research.
- Discovery Biology: Quantifies tight junction function and barrier disruption in response to defined bacterial and chemical stimuli.
- Screening: Provides a robust, quantitative platform for evaluating permeability-modulating compounds.
- Analytics: Enables serial measurement of dextran leakage and supports downstream cytokine and transcriptomic analyses.
- Translational Research: Models disease-relevant epithelial responses, supporting biomarker alignment and preclinical validation.
- Enterprise Reuse: Offers a reusable, adaptable system for diverse barrier function studies across R&D programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation and mechanistic understanding of epithelial barrier dysfunction.
- Operational Value: Delivers standardized, reproducible, and scalable permeability assays for cross-functional teams.
- Strategic Value: Enables informed go/no-go decisions and reduces late-stage biological risk in gastrointestinal portfolios.
- Portfolio Impact: Supports risk-adjusted prioritization of barrier-targeted therapeutics and translational research investments.
Implementation Considerations
- Requires expertise in enteroid culture, microinjection, and immunofluorescent imaging.
- Demands access to specialized instrumentation for microinjection and quantitative fluorescence measurement.
- Necessitates cross-team standardization of assay protocols and data analysis workflows.
- Adaptation to other epithelial or vascular systems may require protocol optimization.
- Careful handling is essential to preserve enteroid structure and ensure assay fidelity.
Biopharma FAQs
Why does null hypothesis testing of LPS-induced permeability matter for target validation?
Null hypothesis testing of LPS-induced permeability in enteroids enables objective evaluation of whether bacterial endotoxins significantly disrupt epithelial barriers, supporting functional validation of tight junction targets. This approach reduces mechanistic ambiguity and informs early-stage go/no-go decisions for barrier-modulating therapeutics.
How does independent variable isolation in dextran microinjection fit the discovery pipeline?
Isolating the effect of specific variables, such as LPS or EGTA, through controlled dextran microinjection allows precise attribution of permeability changes to defined stimuli. This supports mechanistic de-risking and strengthens the predictive value of early discovery assays.
What do quantitative dextran leakage measurements enable in R&D workflows?
Quantitative dextran leakage measurements provide reproducible, dose-dependent readouts of epithelial permeability, enabling direct comparison of experimental conditions and supporting robust screening of candidate modulators. These outputs facilitate data-driven advancement decisions in discovery and preclinical research.
Why are replication requirements critical for cross-functional permeability studies?
Replication ensures that observed permeability changes are consistent and reproducible across enteroid preparations and experimental runs, enabling reliable cross-functional collaboration and assay transferability. This standardization is essential for enterprise-scale R&D and portfolio decision-making.
What statistical analysis capabilities are required before implementing dextran-based permeability assays?
Robust statistical analysis is needed to compare dextran leakage across treatment groups, assess dose-response relationships, and validate assay sensitivity. These capabilities ensure that permeability data support confident target validation and mechanistic interpretation in biopharma pipelines.
Chapters in this video
0:05
Introduction
0:53
Intestinal Epithelial Cell Plating in Basement Membrane Matrix from Whole Specimens
2:54
Immunofluorescent Staining of the Enteroids
3:57
Preparation for Microinjection of Enteroids
6:13
Results: Visualization of Stained Enteroids
7:19
Conclusion
